Acute Colonic Pseudo-Obstruction (Ogilvie's Syndrome)

Acute Colonic Pseudo Obstruction — scientific infographic poster
  1. Overview — What Ogilvie's Syndrome Is
  2. Pathophysiology — Autonomic Imbalance and the Colon
  3. Causes and Risk Factors
  4. Clinical Presentation — Massive Distension Without Obstruction
  5. Diagnosis — Imaging and Distinguishing True Obstruction
  6. Complications — Cecal Perforation and Ischemia
  7. Treatment — Conservative, Neostigmine, and Colonoscopy
  8. Neostigmine — The Ponec Trial (1999) and Practical Use
  9. Surgery — When All Else Fails
  10. Prognosis and Prevention
  11. Key Research Papers
  12. Connections

Overview — What Ogilvie's Syndrome Is

Acute colonic pseudo-obstruction (ACPO), also called Ogilvie's syndrome, is a condition in which the colon undergoes massive dilation in the complete absence of any mechanical blockage. The bowel behaves as though it is obstructed — it stops moving, fills with gas, and distends to dangerous proportions — yet a computed tomography (CT) scan or colonoscopy reveals no tumor, stricture, hernia, or volvulus blocking the lumen. The obstruction is entirely functional: the colon's nervous system is not sending the signals needed for peristalsis.

The syndrome is named for Sir William Heneage Ogilvie, the British surgeon who described two cases in 1948. Both patients had retroperitoneal malignant infiltration of the celiac plexus, and Ogilvie proposed that autonomic nerve involvement disrupted colonic motility. His name has since been attached to the syndrome even in cases with quite different causes.

ACPO is almost exclusively a disease of hospitalized, critically ill patients. It develops after major surgery, trauma, serious medical illness, or prolonged opiate use — situations that overwhelm the autonomic nervous system's regulation of gut function. Recognizing it quickly matters enormously because treatment of ACPO is the opposite of treatment for true mechanical obstruction: surgery is usually the wrong answer for ACPO, while delaying drug treatment allows the colon to dilate further and perforate.

Back to Table of Contents


Pathophysiology — Autonomic Imbalance and the Colon

The colon's motility is governed by the autonomic nervous system through two competing pathways. Parasympathetic innervation — delivered to the left colon and rectum through the pelvic nerves (S2–S4) and to the right colon through the vagus nerve — promotes colonic contractions, peristalsis, and stool propulsion. Sympathetic innervation from the thoracolumbar splanchnic nerves (T6–L2) inhibits colonic motility and promotes fluid absorption and sphincter tone.

In ACPO, this balance is disrupted by an excess of sympathetic tone combined with reduced parasympathetic drive. The inhibitory sympathetic system dominates; the colon stops contracting; gas and fluid accumulate; the bowel dilates massively. The right colon — innervated predominantly by the vagus, which is more vulnerable to disruption in critically ill patients — is disproportionately affected. Gas accumulates primarily in the cecum and ascending colon, which dilate to dramatic diameters.

The cecum is the most vulnerable site for two interconnected reasons:

A cecal diameter exceeding 9–10 cm is considered worrying; a diameter exceeding 12 cm carries significant risk of perforation. Perforation of an unprepared, bacterially colonized colon causes fecal peritonitis, which has a mortality rate exceeding 40% even with prompt surgical intervention.

The pathophysiology explains why pharmacological restoration of parasympathetic tone — using neostigmine, an acetylcholinesterase inhibitor that prolongs the action of acetylcholine at parasympathetic nerve endings — so effectively and rapidly reverses ACPO. Within minutes of neostigmine infusion, the parasympathetic-inhibitory imbalance is corrected, peristalsis resumes, and gas explosively evacuates.

Back to Table of Contents


Causes and Risk Factors

ACPO almost always develops in the context of a serious underlying illness or recent surgery. The trigger is any condition that disrupts autonomic regulation of the colon — creating the sympathetic-parasympathetic imbalance that halts colonic motility.

Post-surgical causes (most common overall):

Medical illness triggers:

Metabolic and electrolyte disturbances:

Medications:

Back to Table of Contents


Clinical Presentation — Massive Distension Without Obstruction

ACPO develops over days rather than hours, distinguishing it from the acute abdominal catastrophe of true mechanical obstruction or colonic volvulus. Patients — typically already in the hospital, recovering from surgery or managing a serious illness — develop a progressively distending abdomen that may become enormous before the underlying condition is recognized.

Cardinal symptoms and signs:

Alarming signs that suggest perforation or ischemia:

The presence of any peritoneal signs transforms the management picture entirely — this is now a surgical emergency regardless of cecal diameter, and the patient requires urgent operative intervention rather than pharmacological decompression.

Back to Table of Contents


Diagnosis — Imaging and Distinguishing True Obstruction

The fundamental diagnostic challenge in ACPO is distinguishing it from large bowel obstruction (LBO) from a mechanical cause — because the treatments are nearly opposite. In LBO, the mechanical blockage must be relieved (surgically or endoscopically) as the primary intervention; pharmacological approaches are ineffective. In ACPO, surgery is usually wrong as a first step and neostigmine or colonoscopic decompression is right.

Plain abdominal radiograph (the first test):

A supine abdominal X-ray is the appropriate first imaging step in a patient with abdominal distension in the hospital setting. In ACPO, the characteristic pattern is:

Computed tomography abdomen and pelvis with intravenous contrast (standard of care for confirmation):

Laboratory evaluation:

Back to Table of Contents


Complications — Cecal Perforation and Ischemia

The serious complications of ACPO arise from two processes that often coexist: ischemic necrosis of the colonic wall from overdistension, and bacterial translocation and perforation when the ischemic wall breaks down.

Ischemic necrosis: As the cecum dilates beyond 10–12 cm, the wall tension calculated by Laplace's Law approaches and then exceeds the perfusion pressure in the submucosal vessels. The mucosa — the most metabolically active and poorly perfused layer — becomes ischemic first. Mucosal ischemia allows intraluminal bacteria to invade the wall layers (bacterial translocation), producing local infection and accelerating wall breakdown. Eventually the full thickness of the wall may become necrotic — a process called transmural ischemia — which typically precedes frank perforation.

Perforation: When the ischemic wall ruptures, the bowel contents — which in an unprepared colon are densely bacterially colonized — spill into the peritoneal cavity. This produces fecal peritonitis, a catastrophic form of bacterial peritonitis with extremely high mortality. In a review of 400 cases, mortality was 36–44% when the bowel was perforated or ischemic, and a 2005 systematic review estimates it at 40% when ischemia or perforation occurs. The high mortality reflects both the severity of fecal peritonitis and the serious underlying conditions these patients already have.

What affects survival: The same review of 400 cases found that the death rate was approximately 15% with early appropriate treatment, and that the type of treatment, the patient's age, the cecal diameter, delay in decompression and the condition of the bowel all significantly influenced it.

Risk thresholds for cecal diameter:

Important caveat: perforation can occur at cecal diameters below 12 cm, particularly if the dilation has been sustained over many days or if the bowel is ischemic. The absence of peritoneal signs does not exclude beginning mucosal ischemia. Serial examination and imaging are essential components of conservative management.

Back to Table of Contents


Treatment — Conservative, Neostigmine, and Colonoscopy

Treatment follows a stepwise approach, escalating from conservative measures to pharmacological intervention to endoscopic decompression to surgery, based on response, cecal diameter, and clinical condition. The presence of peritoneal signs or perforation bypasses this stepwise approach and mandates immediate surgical consultation.

Published guidelines: Two US specialty societies have published guidelines that cover this condition together with colonic volvulus (a twisted colon): the American Society for Gastrointestinal Endoscopy in 2020, on the evaluation and endoscopic management of both conditions, and the American Society of Colon and Rectal Surgeons in 2021, on their management. A 2025 meta-analysis notes that the endoscopy society's guideline places neostigmine before colonoscopy, while a British and Irish coloproctology consensus acknowledges a lack of evidence that either approach is better than the other.

Step 1 — Conservative management (for mild cases: cecal diameter less than 12 cm, no peritoneal signs, duration less than 48–72 hours):

Step 2 — Pharmacological decompression with neostigmine: If conservative measures fail after 24–48 hours, or if cecal diameter is greater than 12 cm at presentation, neostigmine is the first-line pharmacological treatment (covered in detail in the next section). In the same Mayo Clinic series, 16 of the 18 patients given neostigmine (89%) passed gas or stool within 30 minutes, but the response lasted in only 11 of the 18 (61%).

Step 3 — Colonoscopic decompression: For patients in whom neostigmine is contraindicated or who fail to respond to neostigmine, colonoscopic decompression is the next intervention. The procedure is performed without bowel preparation (which is impossible in this setting and potentially dangerous). A colonoscope is advanced as far as possible into the dilated colon, and gas is aspirated as the scope is withdrawn. A decompression tube can be placed in the right colon to maintain decompression after the procedure. Success rates are 70–90% for initial decompression, but recurrence occurs in up to 40% of patients. The procedure is technically challenging because the colon is unprepared, dilated, and the patient is often medically fragile.

Neostigmine compared with colonoscopy: A 2025 meta-analysis pooled the three studies that compared the two options after conservative care had failed, all of them retrospective (looking back at hospital records). Colonoscopic decompression worked in 64 of 77 patients (83%) and neostigmine in 30 of 64 (47%). The authors note that no randomized controlled trial has yet compared the two head to head.

Back to Table of Contents


Neostigmine — The Ponec Trial (1999) and Practical Use

Neostigmine is an acetylcholinesterase inhibitor — it blocks the enzyme that breaks down acetylcholine at the neuromuscular junction and at parasympathetic nerve endings. By prolonging acetylcholine's action, neostigmine restores the parasympathetic drive to the colon, triggers peristaltic contractions, and allows the trapped gas and liquid to be expelled. The response when it works is immediate, dramatic, and unmistakable.

The Ponec Trial (Ponec et al., 1999, NEJM): This landmark randomized placebo-controlled trial established neostigmine as the standard of care for ACPO. Twenty-one patients took part, all with a cecal diameter of at least 10 cm and no response to at least 24 hours of conservative treatment: 11 received a single dose of intravenous neostigmine (2 mg over 3–5 minutes) and 10 received saline placebo. The results were striking:

Practical administration protocol:

Contraindications to neostigmine:

A second dose of neostigmine can be given if the first dose produces a partial response; some protocols allow a second 2 mg dose 3–4 hours after the first if response is incomplete. Repeat dosing beyond two attempts has diminishing returns. After successful decompression with neostigmine, the colon swells again in a share of patients: 2 of the 10 initial responders in the Ponec trial needed colonoscopic decompression for recurrence, and in a Mayo Clinic series 7 of 18 patients given neostigmine (39%) needed colonoscopic decompression or surgery for recurrent or persistent colonic dilation. A repeat dose can be effective for recurrent ACPO.

Keeping the colon from swelling again — polyethylene glycol: In a randomised, placebo-controlled trial of 30 patients whose colonic dilation (cecal diameter of 10 cm or more) had already resolved with neostigmine or endoscopic decompression, half received a daily 29.5 g dose of polyethylene glycol (PEG) electrolyte solution and half a similar placebo, for seven days. Five of the 15 patients on placebo (33.3%) had the cecum swell again, compared with none of the 15 on polyethylene glycol. The polyethylene glycol group also passed more stool and gas and had smaller colon diameters and abdominal circumference. The authors concluded that polyethylene glycol after initial resolution may increase the sustained response rate.

Back to Table of Contents


Surgery — When All Else Fails

Surgery is the treatment of last resort for ACPO in the absence of perforation, and its indications are limited to specific, well-defined scenarios. The key principle is that ACPO is a functional disorder that rarely requires surgical resection of bowel — the colon itself is usually entirely normal and viable once decompression is achieved by other means.

Surgical indications in ACPO:

Surgical options:

In a review of 400 cases, mortality was approximately 15% with early appropriate management, and much of the mortality without perforation reflects the underlying critical illness rather than ACPO itself. Mortality in perforated or ischemic bowel was 36–44% in that review, and a 2005 systematic review estimates it at 40% when ischemia or perforation occurs, underscoring the importance of timely pharmacological intervention to prevent this complication.

Back to Table of Contents


Prognosis and Prevention

The prognosis of ACPO itself — in the absence of perforation and without severe underlying illness — is generally good when recognized and treated promptly. Most patients who receive timely neostigmine decompression recover full colonic function with no long-term consequences. The colon is normal; the disorder is transient autonomic dysfunction; once corrected, the bowel resumes normal activity.

Prognostic factors:

Prevention strategies in high-risk patients:

Back to Table of Contents

Key Research Papers

  1. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999;341(3):137–141. — PubMed PMID: 10403850 · doi:10.1056/NEJM199907153410301 — The foundational RCT demonstrating 91% response rate to IV neostigmine vs 0% placebo.
  2. Ogilvie H. Large-intestine colic due to sympathetic deprivation: a new clinical syndrome. Br Med J. 1948;2(4579):671–673 — PubMed PMID: 18886657 · doi:10.1136/bmj.2.4579.671 — The original 1948 description by Sir William Ogilvie — two patients with celiac plexus involvement and massive colonic dilation.
  3. Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther. 2005;22(10):917–925 — PubMed PMID: 16268965 · doi:10.1111/j.1365-2036.2005.02668.x — Systematic review of epidemiology, pathophysiology, and management of ACPO.
  4. De Giorgio R, Knowles CH. Acute colonic pseudo-obstruction. Br J Surg. 2009;96(3):229–239 — PubMed PMID: 19224517 · doi:10.1002/bjs.6480 — Review of autonomic pathophysiology, clinical recognition, and evidence base for treatment modalities.
  5. Rex DK. Colonoscopy and acute colonic pseudo-obstruction. Gastrointest Endosc Clin N Am. 1997;7(3):499–508 — PubMed PMID: 9177149 — Defines the technique, indications, and outcomes of colonoscopic decompression in ACPO.
  6. Loftus CG, Harewood GC, Baron TH. Assessment of predictors of response to neostigmine for acute colonic pseudo-obstruction. Am J Gastroenterol. 2002;97(12):3118–3122 — PubMed PMID: 12492198 · Search PubMed — Identifies clinical predictors of neostigmine response and recurrence.
  7. Johnson CD, Rice RP, Kelvin FM, Foster WL, Williford ME. The radiologic evaluation of gross cecal distension: emphasis on cecal ileus. AJR Am J Roentgenol. 1985;145(6):1211–1217 — PubMed PMID: 3877425 · doi:10.2214/ajr.145.6.1211 — Establishes radiographic criteria for ACPO and cecal diameter thresholds for perforation risk.
  8. van der Spoel JI, Oudemans-van Straaten HM, Stoutenbeek CP, Bosman RJ, Zandstra DF. Neostigmine resolves critical illness-related colonic ileus in intensive care patients with multiple organ failure — a prospective, double-blind, placebo-controlled trial. Intensive Care Med. 2001;27(5):822–827. — PubMed PMID: 11430537 · doi:10.1007/s001340100926 — Confirms neostigmine efficacy in critically ill ICU patients — a population distinct from the Ponec trial setting.
  9. Mehta R, John A, Nair P, Raj VV, Mustafa CP, Suvarna D, Balakrishnan V. Factors predicting successful outcome following neostigmine therapy in acute colonic pseudo-obstruction: a prospective study. J Gastroenterol Hepatol. 2006;21(2):459–461 — PubMed PMID: 16509875 · doi:10.1111/j.1440-1746.2005.03994.x — Prospective data on neostigmine response predictors in clinical practice.
  10. Trevisani GT, Hyman NH, Church JM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum. 2000;43(5):599–603 — PubMed PMID: 10826417 · doi:10.1007/bf02235569 — Safety profile and outcomes data for neostigmine in a prospective series; supports routine use in appropriately selected patients.
  11. Sgouros SN, Vlachogiannakos J, Vassiliadis K, Bergele C, Stefanidis G, Nastos H, Avgerinos A, Mantides A. Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial. Gut. 2006;55(5):638–642 — PubMed PMID: 16306137 · doi:10.1136/gut.2005.082099 — Randomised placebo-controlled trial of daily polyethylene glycol in 30 patients to prevent ACPO relapse after initial decompression.
  12. Vanek VW, Al-Salti M. Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases. Dis Colon Rectum. 1986;29(3):203–210 — PubMed PMID: 3753674 · doi:10.1007/BF02555027 — Analysis of 400 cases: mortality approximately 15% with early appropriate management versus 36–44% with perforated or ischemic bowel.
  13. Naveed M, Jamil LH, Fujii-Lau LL, Al-Haddad M, Buxbaum JL, Fishman DS, Jue TL, Law JK, Lee JK, Qumseya BJ, Sawhney MS, Thosani N, Storm AC, Calderwood AH, Khashab MA, Wani SB. American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the management of acute colonic pseudo-obstruction and colonic volvulus. Gastrointest Endosc. 2020;91(2):228–235 — PubMed PMID: 31791596 · doi:10.1016/j.gie.2019.09.007 — The 2020 endoscopy-society guideline on evaluation and endoscopic management of ACPO and sigmoid volvulus.
  14. Alavi K, Poylin V, Davids JS, Patel SV, Felder S, Valente MA, Paquette IM, Feingold DL. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colonic Volvulus and Acute Colonic Pseudo-Obstruction. Dis Colon Rectum. 2021;64(9):1046–1057 — PubMed PMID: 34016826 · doi:10.1097/DCR.0000000000002159 — The 2021 colorectal-surgery society guideline on colonic volvulus and ACPO.
  15. Demetriou G, Ghoneim A, Dattani M, Bedford M. Neostigmine Versus Colonoscopic Decompression for Acute Colonic Pseudo-Obstruction Not Resolving With Conservative Measures: A Meta-Analysis. J Surg Res. 2025;313:89–95 — PubMed PMID: 40664115 · doi:10.1016/j.jss.2025.06.032 — Meta-analysis of three retrospective studies: colonoscopic decompression succeeded in 64 of 77 patients, neostigmine in 30 of 64.

Back to Table of Contents

Connections

Back to Table of Contents

Back to Table of Contents